MarketInOut Stock Screener Log In | Sign Up
 

Protagonist Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/08/2026
Protagonist Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,455.58 mln
Float52.59 mln
Earnings Date08/12/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-6.99
Highly reliable

1-Year Forecast

116
Attractive

Relative Strength

28 / 100
Underperforming

Debt / Equity

0.01
Debt-free

ROE

-17.53
Negative

Business Description

Protagonist Therapeutics is a US-based drug discovery and development company focused on creating novel treatments for blood disorders, skin conditions, and obesity. Its most advanced programs include Rusfertide, an injectable treatment in late-stage trials for the rare blood disorder polycythemia vera, and Icotyde, an oral peptide therapy for moderate-to-severe plaque psoriasis. The company has several additional candidates in earlier stages of development targeting conditions such as atopic dermatitis, asthma, and obesity. Founded in 2006 and based in Newark, California, Protagonist has built its pipeline around peptide-based medicines designed to mimic or block naturally occurring proteins in the body.

Key Fundamentals

EPS-1.81
ROE-17.53
RPS1.08
ROIC-105
ROA-16.26
EBITDA, mln-141
EV / EBITDA-42.14
EV / EBIT-41.71
Revenue, mln74.06
EV / Revenue80.24

Financial Strength

Altman Z-Score70.27
Piotroski F-Score 5 / 9
Beneish M-Score-6.99
1-Year Target Price116
Short Ratio8.77
Short % of Float15.30

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 1.01% 59 / 100   
1 Month -4.54% 16 / 100   
2 Months 21.47% 86 / 100   
6 Months 27.58% 85 / 100   
1 Year 131% 92 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us